Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Histotripsy as an Adjunctive Treatment for Biliary Tract Cancer
NCT07853690Recruiting
- Sponsor
- NYU Langone Health
- Start
- Oct 2026
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
Open-label trial in biliary tract cancer (BTC) (2 cohorts), sponsored by NYU Langone Health. Primary endpoints: Objective Response Rate at 24 months, Incidence of Serious Adverse Events at 24 months and 1 more. Started Oct 2026; status: recruiting.
02
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT07853690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07853690.